Written questions by Dillon.

Whether his Department plans to provide additional funding for research into the diagnosis and treatment of invasive lobular breast cancer.

Awaiting answer.

What steps his Department is taking to improve GP awareness and training on vestibular conditions.

Awaiting answer.

What plans he has to expand access to specialist diagnostic services for patients with symptoms of serious balance disorders.

Awaiting answer.

What steps his Department is taking to improve training for healthcare professionals on recognising and managing endometriosis and polycystic ovary syndrome.

Awaiting answer.

What assessment his Department has made of the adequacy of research funding into endometriosis and polycystic ovary syndrome.

The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). In 2024/25, through the NIHR, the Department committed £1.3 million for new research projects on gynaecological conditions and menstrual health, which includes endometriosis and polycystic ovary syndrome. This is building on the existing portfolio commissioned in this area. The NIHR welcomes funding applications for research into any aspect of human health and care, including endometriosis and polycystic ovary syndrome. In recognition that some areas of women’s health have been underserved in research, the Renewed Women’s Health Strategy for England commits to prioritising research through the NIHR in areas of unmet need in women’s health, such as endometriosis and polycystic ovary syndrome.

What funding his Department is providing for research into the genetic differences between people with myalgic encephalomyelitis and those without the condition.

The National Institute for Health and Care Research and the Medical Research Council have dedicated £3.2 million to the DecodeME study. This study aims to understand the genetic differences between those who have myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and those who do not, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments. Preliminary findings from DecodeME indicate genetic differences in eight areas linked to the immune and nervous systems in people with ME/CFS. This discovery of specific genetic signals may help us understand the biological pathways involved in ME/CFS in the future.

What steps he is taking to support people with myalgic encephalomyelitis.

As part of the final delivery plan for myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), that was published in July 2025, the Government committed to supporting people with ME/CFS. The plan focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.We are developing a template service specification for mild and moderate ME/CFS, in conjunction with NHS England. The template will set out examples of best practice for the commissioning of services for ME/CFS to ensure consistent and high-quality care across integrated care boards. The Department, together with ForwardME, is developing a Language Matters Guide to accompany this to ensure that terminology is consistent and well understood.To help support healthcare professionals in the diagnosis and management of ME/CFS, the Department has worked with NHS England to develop an e-learning programme for healthcare professionals. All sessions of the e-learning programme, with sessions one, two, and three having universal access, whilst the final session on managing severe ME/CFS being only available to healthcare professionals, are now available at the following link:https://learninghub.nhs.uk/catalogue/mecfselearning?nodeId=7288.

What steps he is taking to ensure that community pharmacies are adequately funded to maintain opening hours and patient access.

In 2025/26, funding for the core community pharmacy contractual framework was increased to £3.1 billion. This represented the largest uplift in funding of any part of the National Health Service at the time, over 19% across 2024/25 and 2025/26. This included funding for the Pharmacy Access Scheme, which provides additional funding to more isolated pharmacies to support patient access.The Department is currently consulting with Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27. As part of this we will consider financial pressures on the sector.

What steps his Department is taking to support community pharmacies.

As we shift care from hospital and into the community, pharmacies have a vital role to play as an essential front door to the NHS for the public. After years of neglect this Government agreed a record uplift of 3.1 billion pounds for pharmacies in 25/26, a 19% increase over two years. We are also currently consulting with Community Pharmacy England on funding arrangements to support pharmacies in 2026/27.

What assessment he has made of the potential role of community pharmacies in delivering a MenB vaccination catch-up programme for students and other at-risk groups.

The Government is looking to expand the number of vaccines offered in community pharmacies across the country through local, targeted vaccination programmes. This has already started, with NHS England commissioning some community pharmacies in the Midlands, North-West, London, and East of England to help deliver the year-round respiratory syncytial virus vaccination programmes to eligible pregnant women, to protect newborns, and adults aged 75 to 79 years old as well as the year-round Pertussis vaccination programme to eligible pregnant women.NHS England also nationally commissioned community pharmacies to administer flu vaccines for two and three year olds for the first time in autumn 2025. An evaluation will assess whether this use of community pharmacies improves vaccine uptake and helps tackle regional health inequalities, in line with the NHS Vaccination Strategy.The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.On the 17 March, my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that he would ask the JCVI to review eligibility for meningococcal B (MenB) vaccination. The JCVI will conduct a full assessment of the cost-effectiveness of a routine adolescent MenB vaccination programme and provide a complete and formal response to my Rt Hon. Friend, the Secretary of State for Health and Social Care as soon as practicable.The Department, the UK Health Security Agency, and NHS England will continue to ensure arrangements are place to ensure that everyone who is eligible for MenB vaccination can access vaccinations via appropriate care routes.

Whether his Department is considering commissioning MenB vaccination programmes through community pharmacies.

The Government is looking to expand the number of vaccines offered in community pharmacies across the country through local, targeted vaccination programmes. This has already started, with NHS England commissioning some community pharmacies in the Midlands, North-West, London, and East of England to help deliver the year-round respiratory syncytial virus vaccination programmes to eligible pregnant women, to protect newborns, and adults aged 75 to 79 years old as well as the year-round Pertussis vaccination programme to eligible pregnant women.NHS England also nationally commissioned community pharmacies to administer flu vaccines for two and three year olds for the first time in autumn 2025. An evaluation will assess whether this use of community pharmacies improves vaccine uptake and helps tackle regional health inequalities, in line with the NHS Vaccination Strategy.The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.On the 17 March, my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that he would ask the JCVI to review eligibility for meningococcal B (MenB) vaccination. The JCVI will conduct a full assessment of the cost-effectiveness of a routine adolescent MenB vaccination programme and provide a complete and formal response to my Rt Hon. Friend, the Secretary of State for Health and Social Care as soon as practicable.The Department, the UK Health Security Agency, and NHS England will continue to ensure arrangements are place to ensure that everyone who is eligible for MenB vaccination can access vaccinations via appropriate care routes.

What assessment he has made of the cost-effectiveness of commissioning MenB vaccination programmes through community pharmacies.

The Government is looking to expand the number of vaccines offered in community pharmacies across the country through local, targeted vaccination programmes. This has already started, with NHS England commissioning some community pharmacies in the Midlands, North-West, London, and East of England to help deliver the year-round respiratory syncytial virus vaccination programmes to eligible pregnant women, to protect newborns, and adults aged 75 to 79 years old as well as the year-round Pertussis vaccination programme to eligible pregnant women.NHS England also nationally commissioned community pharmacies to administer flu vaccines for two and three year olds for the first time in autumn 2025. An evaluation will assess whether this use of community pharmacies improves vaccine uptake and helps tackle regional health inequalities, in line with the NHS Vaccination Strategy.The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.On the 17 March, my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that he would ask the JCVI to review eligibility for meningococcal B (MenB) vaccination. The JCVI will conduct a full assessment of the cost-effectiveness of a routine adolescent MenB vaccination programme and provide a complete and formal response to my Rt Hon. Friend, the Secretary of State for Health and Social Care as soon as practicable.The Department, the UK Health Security Agency, and NHS England will continue to ensure arrangements are place to ensure that everyone who is eligible for MenB vaccination can access vaccinations via appropriate care routes.

How many new Fracture Liaison Services have been established since July 2024.

Our 10-Year Health Plan committed to rolling out Fracture Liaison Services (FLSs) across every part of the country by 2030. The Department does not routinely collect data on the number of FLSs. The Falls and Fragility Fracture Audit Programme, which includes a dedicated FLS database, is a clinical audit of fracture prevention care, delivered by the Royal College of Physicians. The FLS database collects, measures, and reports on the care provided by FLSs in England, Wales, and Northern Ireland. It does not include opening and closing dates of FLSs but provides an annual snapshot of the number of FLSs that have submitted data. The database is available at the following link: https://www.fffap.org.uk/FLS/charts.nsf/benchmarks?ReadForm&yr=2025&vw=BALL&org1= The Royal College of Physicians publishes an annual report on FLSs in England and Wales, which is available at the following link: https://www.rcp.ac.uk/95436

What steps his Department is taking to ensure that NHS trusts collect complete data on the diagnosis, treatment and care of people with secondary breast cancer.

The Government recognises the importance of robust, comprehensive data on secondary, or metastatic, breast cancer to improve patient outcomes, inform research, and support effective workforce and service planning.Through the National Cancer Plan, for the first time, we have committed to delivering the systemic definition, identification, and counting of recurrent and metastatic cancers, starting with metastatic breast cancer, addressing longstanding gaps in national data on secondary disease.To improve data collection, the National Disease Registration Service’s Get Data Out programme is strengthening the scope, quality, and accessibility of cancer data. This includes expanding the data made available to the public, clinicians, and researchers on incidence, routes to diagnosis, treatments, and survival.This data is used to support cancer research and outcomes analysis, to inform service and workforce planning, including understanding demand for specialist roles such as breast cancer clinical nurse specialists, and to provide real‑world evidence to support assessments of clinical and cost effectiveness used in commissioning and appraisal processes. NHS England is also taking action to improve the completeness and consistency of data collected by National Health Service trusts. This includes funding national audits for primary and metastatic breast cancer using routinely collected NHS data. These audits assess diagnosis, treatment, and care pathways, identify variation in practice, and highlight areas where data quality or service delivery can be improved.On 11 September 2025, the second State of the Nation report for primary and metastatic breast cancer was published by the National Cancer Audit Collaborating Centre, and officials in the Department and NHS England are acting on the findings where appropriate, including to strengthen data quality across trusts.

What timetable his Department has set for decisions on a second wave of National Service Frameworks; and whether respiratory conditions are under consideration.

The Government will consider the long-term conditions for future waves of modern service frameworks (MSFs), including respiratory conditions. The criteria for determining other conditions for future MSFs will be based on where there is potential for rapid and significant improvements in quality of care and productivity. In relation to timing, after the initial wave of MSFs is complete, the National Quality Board will determine the conditions to prioritise for new MSFs as part of its work programme.

Whether his Department plans to conduct a review of NHS weight management services, including their eligibility criteria.

The National Health Service and local government provide a range of weight management services. Commissioning and funding decisions for obesity services are made locally. NHS integrated care boards, local authorities, and NHS England are expected to take National Institute for Health and Care Excellence (NICE) guidance into account when designing services.NICE guidance on overweight and obesity management sets out the core components, standards, and eligibility criteria for weight management programmes.In this context, the Department has no current plans to review NHS weight management services, or their eligibility criteria. The Department and NHS England continue to provide national policy direction, including by providing commissioning guidance for local systems. We are committed to expanding access to obesity medicines and expanding the NHS Digital Weight Management Programme to support an additional 125,000 people over the next three years.

When his Department plans to publish guidance on Neighbourhood Health Plans.

No specific assessment has been made of the potential impact of the time taken to publish guidance on community health services. We are developing guidance on Neighbourhood Health Plans to provide greater clarity and consistency for systems in developing and scaling neighbourhood health. We expect this to be available soon.Our upcoming guidance will build on and complement our existing set of publications that set out the actions needed to lay the groundwork for a Neighbourhood Health Service. This suite of guidance, which includes the NHS Medium Term Planning Framework for 2026/27 to 2028/29, the strategic commissioning framework for integrated care boards (ICBs), and the Model Region and ICB blueprints, supports National Health Service operational planning and joined-up partnership work between local government and ICBs.

What assessment he has made of the potential impact of the time taken to publish guidance on Neighbourhood Health Plans on community health services.

No specific assessment has been made of the potential impact of the time taken to publish guidance on community health services. We are developing guidance on Neighbourhood Health Plans to provide greater clarity and consistency for systems in developing and scaling neighbourhood health. We expect this to be available soon.Our upcoming guidance will build on and complement our existing set of publications that set out the actions needed to lay the groundwork for a Neighbourhood Health Service. This suite of guidance, which includes the NHS Medium Term Planning Framework for 2026/27 to 2028/29, the strategic commissioning framework for integrated care boards (ICBs), and the Model Region and ICB blueprints, supports National Health Service operational planning and joined-up partnership work between local government and ICBs.

What plans he has to review the NHS dental banding system to reflect the treatment of patients with complex needs.

We are introducing three new care pathways for patients with significant dental decay and gum disease, with payments to dentists ranging from £248 to £709.Under the new care pathways, patients will agree a single care plan with their dentist, setting out the prevention, treatment, and appointments they need. Patients will pay one charge for the whole course of care, normally a Band 2 charge. This approach benefits patients by reducing the need for repeated visits and avoiding multiple charges, while supporting more effective, joined‑up care.By incentivising complex treatments, we’re encouraging dentists to undertake vital National Health Service work, benefiting patients across the country who will pay one charge for the whole course of treatment.We are committed to delivering fundamental reform of the dental contract before the end of this Parliament. As a first step, on 16 December we published the Government’s response to the public consultation on quality and payment reforms to the NHS dental contract. The changes will be introduced from April 2026. These reforms will put patients with greatest need first, incentivising urgent care and complex treatments. Further information is available from the following link: https://www.gov.uk/government/consultations/nhs-dentistry-contract-quality-and-payment-reforms/outcome/government-response-to-consultation-on-nhs-dentistry-contract-quality-and-payment-reforms

What steps he is taking to improve child dental health in Newbury constituency.

The 10-Year Health Plan confirms that child dental health is a priority. We are introducing changes to dental access that will benefit children. Following public consultation, from April 2026 we will introduce a new course of treatment for fluoride varnish for children to be applied by suitably trained dental nurses in between regular check-ups. We will also increase remuneration for dentists for fissure sealants, to support increased use of this effective treatment for primary prevention purposes.In the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board, 26,221, or 12%, more NHS dental treatments were delivered to children in April to October 2025 compared to the same period before the election.The Government is also prioritising the prevention of poor dental health in children. Through the national supervised toothbrushing programme, the West Berkshire Council has been allocated approximately £33,000 over the 2025/26 and 2026/27 financial years to target three- to five-year-olds in deprived areas. The West Berkshire Council has also received approximately 700 free toothbrushes and toothpastes through our five year collaboration with Colgate-Palmolive.